Pro Pharmaceuticals: Subsidiary has obtained the drug registration certificate for the sustained-release theobromine tablet, specification 0.4g.

ProLo Pharmaceutical announced that its holding subsidiary, Zhejiang ProLo Kangyu Pharmaceutical Co., Ltd., has received the "Drug Registration Certificate" for ketorolac extended-release tablets issued by the National Medical Products Administration. The drug specification is 0.4g, registered as a Class 3 chemical drug, with both the marketing authorization holder and the manufacturing company being Zhejiang ProLo Kangyu Pharmaceutical Co., Ltd. Ketorolac extended-release tablets are peripheral vasodilators, and according to relevant data, the domestic market size for this product is expected to be approximately 52.27 million tablets in 2025, with sales amounting to around 262 million yuan. The companys product has been approved as a Class 3 chemical drug, which is considered equivalent to passing the consistency evaluation for generic drugs.